Malignant Vulvar Neoplasm — Trials

Malignant Vulvar Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

184 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 54
Recruiting: 32
Ph III recruiting: 1
Growth YoY: —
Industry share: 19%
Top sponsor: National Cancer Institute (NCI)
Termination share: 21.3%
Trials / 1,000 deaths: 36.6 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (14)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05932212	AK104 for Recurrent or Metastatic Vulvar Cancer	terminated	Phase 2	20	AkesoINDUSTRY	1	Sep 28, 2026	clinicaltrials
NCT03439085	DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers	terminated	Phase 2	41	M.D. Anderson Cancer CenterOTHER	1	Jul 9, 2024	clinicaltrials